GOVX קפיטליזציה חשבונאית GeoVax

GeoVax Labs, Inc. (GOVX) focuses on developing anti-tumor and antiviral vaccines, with costs concentrated in R&D, which will ensure a sharp increase in profit when transitioning to external manufacturing. This daily price chart, which reached 0.00, accompanies the business of commercializing genetic delivery platforms. However, success depends on government grants and private investments, and early-stage testing carries the risk of failure.

This metric calculates the total net assets of GeoVax Labs, Inc. (GOVX) minus liabilities, providing a real-time reflection of how quarterly reports impact the business's fundamental value. The current value of 0.00 on the company's book capitalization chart demonstrates how the market consensus assesses the tangible basis of this developer of innovative vaccines and immunotherapeutic platforms, allowing investors to determine the extent of the premium paid for the brand's scientific potential.